Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December

Cue Biopharma, Inc. (NASDAQ:CUE) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,080,000 shares, a growth of 8.0% from the November 30th total of 1,000,000 shares. Based on an average daily trading volume, of 787,600 shares, the days-to-cover ratio is presently 1.4 days.

Insider Activity

In other Cue Biopharma news, CEO Daniel R. Passeri acquired 30,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were acquired at an average price of $1.03 per share, with a total value of $30,900.00. Following the completion of the transaction, the chief executive officer now directly owns 164,578 shares in the company, valued at $169,515.34. This trade represents a 22.29 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.26% of the company’s stock.

Institutional Trading of Cue Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after acquiring an additional 16,371 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of Cue Biopharma by 5.1% in the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after purchasing an additional 14,104 shares during the last quarter. Sigma Planning Corp increased its holdings in shares of Cue Biopharma by 50.9% in the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after purchasing an additional 135,295 shares during the last quarter. Good Life Advisors LLC increased its holdings in shares of Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cue Biopharma in the second quarter valued at $66,000. 35.04% of the stock is owned by institutional investors.

Cue Biopharma Stock Performance

Shares of CUE stock opened at $1.09 on Thursday. The company’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $1.01. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The firm has a market cap of $69.05 million, a PE ratio of -1.21 and a beta of 1.66. Cue Biopharma has a 12 month low of $0.45 and a 12 month high of $3.20.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.